The Federal Republic of Germany agreed to invest $337m in CureVac, a biopharmaceutical company headquartered in Tübingen, that develops therapies based on messenger RNA. Under the agreement, the state will hold a stake of around 23% in CureVac. "We are very excited that, with the Federal Republic of Germany and dievini, we have such strong and reliable partners at our side. This strong financial commitment provides us further cash reach and stability for the accelerated development of our mRNA platform, the development and production of our current and additional mRNA vaccine and drug candidates, as well as the strategic expansion of our organization. At the same time we will retain full operational and strategic independence," Franz-Werner Haas, CureVac Acting CEO and COO.